Rheumatoid arthritis
Conditions
Interventions
Administer MTX 6-16mg/week for 12 weeks to patients with MDA-RA. If patients can'
t take MTX, administer IGU 25-50mg/day or Tac 1.5-3.0mg/day for 12 weeks.
Administer ADA 40mg/2weeks for 24weeks additionally, in case of MDA taking MTX or IGU, Tac for 12 weeks.
If patients maintai
Sponsors
Zenjinkai Shimin-no-mori Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with MDA-RA who take other csDMARDs and Steroid more than 3months.
Exclusion criteria
Exclusion criteria: Patients who contraindicate for IGU, Tac or ADA. In case of MTX group, patients who contraindicate for MTX. Patients who can't provide informed concent. Patients who have malignancy. Patients who judged to be disqualified by the physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DAS28-CRP remission rate at 12weeks, 36weeks and 108weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) DAS28-CRP LDA rate at 12weeks, 36weeks and 108weeks 2) Change of ADL(Delta HAQ-DI) 3) Adverse event 4) The factors for each outcomes | — |
Countries
Japan
Contacts
Public ContactToshihiko Hidaka MD. PhD.
Zenjinkai Shimin-no-mori Hospital Insutitution of Rheumatology
Outcome results
None listed